Literature DB >> 14665975

The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats.

P J McLaughlin1, K Winston, L Swezey, A Wisniecki, J Aberman, D J Tardif, A J Betz, K Ishiwari, A Makriyannis, J D Salamone.   

Abstract

Cannabinoid CB1 receptor agonists, including delta-9-tetrahydrocannabinol (Delta 9-THC) (the main psychoactive ingredient in marijuana) have been shown to increase feeding in rats and humans. Conversely, it has been reported that acute administration of the CB1 receptor antagonist SR 141716A reduces food intake in rats. Based upon this observation, it has been suggested that CB1 antagonists could be useful as appetite suppressant drugs. The present studies were designed to provide a detailed examination of the effects of CB1 antagonists on food intake across a range of paradigms. Two CB1 antagonists (SR 141716A and AM 251) were administered to rats trained on fixed-ratio schedules with two different ratio requirements (fixed-ratio 1 and fixed-ratio 5). Both drugs produced a dose-dependent decrease in lever pressing, and had a relatively long duration of action (T1/2: SR 141716A, 15.1 h; AM 251, 22.0 h). Furthermore, intake of three diets with differing macronutrient composition (lab chow, high fat, high carbohydrate) was studied. Both drugs significantly suppressed intake of all three foods, and there were no significant interactions between drug dose and diet type. These findings support the hypothesis that CB1 receptor antagonists could be useful pharmacological tools for the suppression of appetite.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14665975     DOI: 10.1097/00008877-200312000-00002

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  61 in total

1.  A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.

Authors:  N L Cluny; V K Vemuri; A P Chambers; C L Limebeer; H Bedard; J T Wood; B Lutz; A Zimmer; L A Parker; A Makriyannis; K A Sharkey
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Rimonabant.

Authors:  Sheridan Henness; Dean M Robinson; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Cannabinoid facilitation of behavioral and biochemical hedonic taste responses.

Authors:  M A De Luca; M Solinas; Z Bimpisidis; S R Goldberg; G Di Chiara
Journal:  Neuropharmacology       Date:  2011-11-02       Impact factor: 5.250

4.  Cannabinoid action in the olfactory epithelium.

Authors:  Dirk Czesnik; Detlev Schild; Josko Kuduz; Ivan Manzini
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-14       Impact factor: 11.205

Review 5.  Hypothalamic regulatory pathways and potential obesity treatment targets.

Authors:  Erin E Jobst; Pablo J Enriori; Puspha Sinnayah; Michael A Cowley
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

6.  Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor.

Authors:  Peter J McLaughlin; Julia E Jagielo-Miller; Emily S Plyler; Kerry K Schutte; V Kiran Vemuri; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2017-02-01       Impact factor: 4.530

7.  The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats.

Authors:  Kelly S Sink; Peter J McLaughlin; Jodi Anne T Wood; Cara Brown; Pusheng Fan; V Kiran Vemuri; Yan Peng; Yan Pang; Teresa Olszewska; Teresa Olzewska; Ganesh A Thakur; Alex Makriyannis; Linda A Parker; John D Salamone
Journal:  Neuropsychopharmacology       Date:  2007-06-20       Impact factor: 7.853

Review 8.  Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions.

Authors:  John D Salamone; Peter J McLaughlin; Kelly Sink; Alexandros Makriyannis; Linda A Parker
Journal:  Physiol Behav       Date:  2007-04-14

9.  Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142.

Authors:  K S Sink; K N Segovia; J Sink; P A Randall; L E Collins; M Correa; E J Markus; V K Vemuri; A Makriyannis; J D Salamone
Journal:  Eur Neuropsychopharmacol       Date:  2009-12-16       Impact factor: 4.600

10.  Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers.

Authors:  David Ted George; David W Herion; Cheryl L Jones; Monte J Phillips; Jacqueline Hersh; Debra Hill; Markus Heilig; Vijay A Ramchandani; Christopher Geyer; David E Spero; Erick D Singley; Stephanie S O'Malley; Raafat Bishai; Robert R Rawlings; George Kunos
Journal:  Psychopharmacology (Berl)       Date:  2009-11-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.